Browsing Tag
Ying Huang
2 posts
Legend Biotech (NASDAQ: LEGN) CARVYKTI scaling meets LB2102 solid tumor signal
Legend Biotech (NASDAQ: LEGN) printed 62% CARVYKTI growth and a solid tumor CAR-T signal. The 2026 profitability target is the next real test.
June 23, 2026
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA)…
May 28, 2023